構造的に多様な6デオキシテトラサイクリン抗生物質への収束性エナンチオセレクティブ経路
Mark G Charest1, Christian D Lerner, Jason D Brubaker
1Department of Chemistry and Chemical Biology, Harvard University, Cambridge, MA 02138, USA.
まとめ
研究者らは,多様な6-デオキシテトラサイクリン抗生物質のための新しい合成経路を開発し,潜在的な抗生物質候補を拡大しました. この方法により,特にD環の構造的な変化が可能になり,従来の半合成の限界を克服します.
科学分野:
- 有機化学 オーガニック・ケミストリー
- 薬用化学 薬用化学について
- 合成生物学 合成生物学とは
背景:
- 複雑な抗生物質は,通常,半合成による天然製品から得られます.
- 半合成は,構造的多様性と新しい抗生物質候補の探索を制限する.
- 新種の合成経路の開発は,抗生物質医薬品発見パイプラインの拡大に不可欠です.
研究 の 目的:
- 6デオキシテトラサイクリン抗生物質の多様な範囲のための短い,エナンチオセレクティブの合成経路を確立する.
- 新しい抗生物質の開発のために,Dリングに焦点を当てた構造的多様性を可能にします.
- 新しい抗生物質構造へのアクセスにおける半合成の限界を克服するために.
主な方法:
- 後期段階のダイアステレオセレクティブCリングの建設戦略を開発しました.
- 構造的に異なるDリング前駆体とAB前駆体を組み合わせた.
- 合成の材料としてベンゾ酸を使用した.
主要な成果:
- 6デオキシテトラサイクリン抗生物質の5つの誘導体を14〜15のステップで5〜7%の収量で合成しました.
- 合成された (-) -ドキシサイクリンが8.3%で18段階にわたって生成されます.
- 多様な抗生物質構造を生み出すための汎用性の高い合成アプローチを示した.
結論:
- 開発された合成経路は,6-デオキシテトラサイクリン構造の幅広い範囲にアクセスできます.
- このアプローチは,天然製品の制限を超えて,潜在的な抗生物質候補の範囲を大幅に拡大します.
- この方法論は,抗生物質開発のための構造-活性関係の研究を容易にする.
関連する概念動画
Antibiotic Selection
Overview
The Electron Transport Chain
The electron transport chain or oxidative phosphorylation is an exothermic process in which free energy released during electron transfer reactions is coupled to ATP synthesis. This process is a significant source of energy in aerobic cells, and therefore inhibitors of the electron transport chain can be detrimental to the cell's metabolic processes.
Inhibitors of the electron transport chain
Rotenone, a widely used pesticide, prevents electron transfer from Fe-S cluster to ubiquinone or Q in...
Inhibitors of the electron transport chain
Rotenone, a widely used pesticide, prevents electron transfer from Fe-S cluster to ubiquinone or Q in...
Combined Effects of Drugs: Synergism
Synergism is a useful mechanism where combining two or more drugs is more effective than each constituent used alone. Such combinations are also called supra-additive interactions. The drugs collectively enhance the final therapeutic effect by acting on different targets. Another advantage is that the low dose of each constituent drug is sufficient to achieve the desired effect. This helps reduce the duration of therapy and lower the adverse effects of these drugs.
Such synergistic combinations...
Such synergistic combinations...
Production of Antibiotics
Penicillin, one of the earliest and most widely used antibiotics, is produced industrially by the filamentous fungus Penicillium chrysogenum. Large stirred-tank bioreactors ranging from tens to hundreds of thousands of liters maintain tightly controlled temperature, pH, and dissolved oxygen conditions to support fungal metabolism and maximize antibiotic yield. Penicillin is a secondary metabolite, synthesized primarily during the stationary growth phase, which requires a carefully managed...
Production of Pharmaceuticals
Industrial insulin production uses genetically engineered E. coli expressing a proinsulin gene controlled by a tryptophan promoter and containing a methionine linker for later cleavage. The cells also carry ampicillin resistance for selective growth. Seed cultures are stored at −80 °C and production begins by thawing a small amount to inoculate starter cultures, which are progressively scaled to a 50,000-L bioreactor. In the bioreactor, E. coli grow in nutrient-rich media under sterile, tightly...
Antifungal Agents
Amphotericin B is a broad-spectrum antifungal agent that exploits structural differences between fungal and mammalian cell membranes. Its amphipathic structure—featuring a hydrophobic polyene-lactone ring and a hydrophilic region containing mycosamine and carboxylic acid groups—enables selective binding to ergosterol, a sterol predominantly found in fungal plasma membranes. This selective interaction underlies the drug’s antifungal activity, although weak binding to cholesterol contributes to...


